Trial
NCT04757610
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Opthea Limited
Collaborators
—
Condition
Neovascular Age-related Macular Degeneration
Intervention
2.0 mg OPT-302
Why stopped
The primary endpoint was not achieved in the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-22